Insilico Medicine Explores Abu Dhabi Secondary Listing 5 Months After Hong Kong IPO
Updated
Updated · Bloomberg · May 26
Insilico Medicine Explores Abu Dhabi Secondary Listing 5 Months After Hong Kong IPO
1 articles · Updated · Bloomberg · May 26
Insilico Medicine has begun preliminary talks on a secondary listing on the Abu Dhabi Securities Exchange, with a deal possible as early as 2026, according to people familiar with the matter.
The Hong Kong-listed biotech would become the first company from outside the Gulf to list shares on a regional exchange if the plan proceeds.
Insilico only went public in Hong Kong in December, making the Abu Dhabi discussions an early move to broaden its capital-markets footprint.
Is Insilico's pioneering Abu Dhabi listing creating a new 'biotech silk road' between Asia and the Middle East?
Insilico’s AI found a potential IPF cure in 30 months. What does its Abu Dhabi move mean for other incurable diseases?